康龙化成“落子”杭州,CXO“延链补链”如何平衡?

盖德化工网
Feb 03

那头,仿转创CRO阳光诺和刚终止对朗研生命的二次并购,不继续向下游制造延链,把资源集中到新药研发领域,寄望以研发撬动授权合作(含管线与技术授权)常态化变现这头,实验室服务起家、做大的CXO龙头康龙化成已完成在杭州的“落子”布局,是重大补链、强链动作。两件事情凑一起看,巨头“补链强链”不怎么声张就落地,中小CRO一场延链并购交易反复拉锯4年,最终宣告“夭折”。这种两极分化下,CXO当下流行的“延链...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10